Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34


The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.

Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD.

Cancer Med. 2020 Mar 18. doi: 10.1002/cam4.2998. [Epub ahead of print]


Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes.

Anagnostou T, Sakemura R, Forsman CL, Patnaik MS, Paludo J, Gastineau DA, Buadi FK, Porrata LF, Kumar SK, Gertz MA, Lacy MQ, Dispenzieri A, Gonsalves WI, Lehman JS, Hogan WJ, Hashmi SK, Alkhateeb H, Shah MV, Litzow MR, Kenderian SS.

Bone Marrow Transplant. 2020 Mar 11. doi: 10.1038/s41409-020-0851-3. [Epub ahead of print] No abstract available.


The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor.

Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA.

Haematologica. 2020 Jan 23. pii: haematol.2019.240564. doi: 10.3324/haematol.2019.240564. [Epub ahead of print] No abstract available.


Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA.

Am J Hematol. 2020 Mar;95(3):E57-E60. doi: 10.1002/ajh.25690. Epub 2019 Dec 13. No abstract available.


Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies.

Sterner RM, Kenderian SS.

Curr Opin Hematol. 2020 Jan;27(1):41-48. doi: 10.1097/MOH.0000000000000559.


Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.

Sterner RM, Cox MJ, Sakemura R, Kenderian SS.

J Vis Exp. 2019 Jul 22;(149). doi: 10.3791/59629.


Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.


Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

Khadka RH, Sakemura R, Kenderian SS, Johnson AJ.

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4. No abstract available.


Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.


CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.

Mochel JP, Ekker SC, Johannes CM, Jergens AE, Allenspach K, Bourgois-Mochel A, Knouse M, Benzekry S, Wierson W, LeBlanc AK, Kenderian SS.

AAPS J. 2019 Apr 8;21(3):50. doi: 10.1208/s12248-019-0322-1. Review.


IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.


GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS.

Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21.


Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside.

Rodriguez-Cartagena LG, Bowles BS, Kurani SS, Windebank AJ, Kenderian SS, Greenberg-Worisek AJ.

Clin Transl Sci. 2018 Nov;11(6):537-539. doi: 10.1111/cts.12586. Epub 2018 Sep 22. No abstract available.


Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA.

Br J Haematol. 2018 Nov;183(3):421-427. doi: 10.1111/bjh.15545. Epub 2018 Aug 16.


Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.

Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31.


Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.

Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD.

Haematologica. 2018 Jun;103(6):e237-e240. doi: 10.3324/haematol.2017.183194. Epub 2018 Feb 1. No abstract available.


Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.

Ruella M, Kenderian SS.

BioDrugs. 2017 Dec;31(6):473-481. doi: 10.1007/s40259-017-0247-0. Review.


Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.

Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Am J Hematol. 2017 Dec;92(12):1362-1369. doi: 10.1002/ajh.24915. Epub 2017 Oct 19.


Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.

Kenderian SS, June CH, Gill S.

Methods Mol Biol. 2017;1633:267-276. doi: 10.1007/978-1-4939-7142-8_17.


Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.


Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.


Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Leuk Lymphoma. 2017 Jun;58(6):1376-1383. doi: 10.1080/10428194.2016.1251592. Epub 2016 Nov 8.


Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28. No abstract available.


Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.

Kenderian SS, Porter DL, Gill S.

Biol Blood Marrow Transplant. 2017 Feb;23(2):235-246. doi: 10.1016/j.bbmt.2016.09.002. Epub 2016 Sep 13. Review.


Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.


The Microbiome and Immune Regulation After Transplantation.

Tabibian JH, Kenderian SS.

Transplantation. 2017 Jan;101(1):56-62. doi: 10.1097/TP.0000000000001444. Review.


Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS.

Blood. 2016 Apr 21;127(16):1960-6. doi: 10.1182/blood-2015-08-665505. Epub 2016 Feb 2.


The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.


Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation.

Kenderian SS, Rosado FG, Sykes DB, Hoyer JD, Lacy MQ.

Leukemia. 2015 Dec;29(12):2414-6. doi: 10.1038/leu.2015.298. Epub 2015 Oct 26. No abstract available.


CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.

Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.


Chimeric antigen receptor T-cell therapy to target hematologic malignancies.

Kenderian SS, Ruella M, Gill S, Kalos M.

Cancer Res. 2014 Nov 15;74(22):6383-9. doi: 10.1158/0008-5472.CAN-14-1530. Epub 2014 Nov 4.


Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist.

Rosado FG, Oliveira JL, Sohani AR, Schroyens W, Sykes DB, Kenderian SS, Lacy MQ, Kyle RA, Hoyer JD.

Mod Pathol. 2015 Mar;28(3):367-72. doi: 10.1038/modpathol.2014.117. Epub 2014 Sep 12.


Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage.

Sonbol MB, Rana V, Kenderian SS, Finnes H, Witzig TE.

Leuk Lymphoma. 2014 Aug;55(8):1815-21. doi: 10.3109/10428194.2013.828349. Epub 2013 Dec 31.


Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia.

Kenderian SS, Al-Kali A, Gangat N, Letendre L, Hogan WJ, Litzow MR, Patnaik MM.

Blood Cancer J. 2013 Jul 5;3:e122. doi: 10.1038/bcj.2013.21. No abstract available.

Supplemental Content

Loading ...
Support Center